Breast Implant Update: Scrutiny Continues
At an FDA General and Plastic Surgery Devices panel held in August to make recommendations on postmarketing issues related to silicone gel breast implants, the agency said it will continue to monitor patient safety via the postapproval studies and surgeon adverse reports and has asked that groups work together to improve follow-up and registry enrollment.
You may also be interested in...
The stem cell market is beginning to show signs of significant revenue growth ahead, a development fueled by research in a variety of disease categories, some of which has already produced accepted therapies. In February, about three dozen firms gathered at the 5th Annual Stem Cell Summit, where participants showcased their technology in the hopes of securing financing.
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.